LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial

Autor: Petrie, JR, Marso, SP, Bain, SC, Franek, E, Jacob, S, Masmiquel, L, Leiter, LA, Haluzik, M, Satman, I, Omar, M, Shestakova, M, Van Gaal, L, Mann, JF, Baeres, FM, Zinman, B, Poulter, NR, LEADER investigators

Publikováno v: Journal of hypertension
Journal of Hypertension

Objective: As glucagon-like peptide-1 receptor agonists lower blood pressure (BP) in type 2 diabetes mellitus (T2DM), we examined BP control in relation to targets set by international bodies prior to randomization in the Liraglutide Effect and Actio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76bde80e35bc7f47df055c0d2b64ac39
https://eprints.gla.ac.uk/116246/1/116246.pdf

LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.

Autor: Petrie JR; aInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK bDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, USA cInstitute of Life Science, College of Medicine, Swansea University Medical School, Swansea, UK dMossakowski Medical Research Centre, Polish Academy of Sciences eDepartment of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital MSW, Warsaw, Poland fKardio Metabolischen Instituts, Villingen-Schwenningen, Germany gEndocrinology and Nutrition Department, Hospital Son Llàtzer, University Institute of Health Science Research (IUNICS)-Universitat de les Illes Balears, Palma de Mallorca, Spain hDivisions of Endocrinology & Metabolism, Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, Ontario, Canada i1st Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic jDivision of Endocrinology and Metabolism, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey kDepartment of Diabetes and Endocrinology, Nelson R Mandela School of Medicine, University of KwaZulu Natal, South Africa lEndocrinology Research Centre, Diabetes Institute mI.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation nFaculty of Medicine, Antwerp University Hospital, Antwerp, Belgium oDepartment of Nephrology, Hypertension & Rheumatology, Friedrich Alexander University of Erlangen, Munchen, Germany pNovo Nordisk, A/S, Bagsvaerd, Denmark qLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada rInternational Centre for Circulatory Health, Imperial College London, London, UK., Marso SP, Bain SC, Franek E, Jacob S, Masmiquel L, Leiter LA, Haluzik M, Satman I, Omar M, Shestakova M, Van Gaal L, Mann JF, Baeres FM, Zinman B, Poulter NR

Publikováno v: Journal of hypertension [J Hypertens] 2016 Jun; Vol. 34 (6), pp. 1140-50.

LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.

Autor: Masmiquel L; Endocrinology and Nutrition Department, Hospital Son Llàtzer, University Institute of Health Science Research (IUNICS-IdISPa), Universitat de les Illes Balears, Palma, Majorca, Spain. lmasmiquel@gmail.com., Leiter LA; Divisions of Endocrinology and Metabolism, Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. leiterl@smh.ca., Vidal J; Endocrinology and Nutrition Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. JOVIDAL@clinic.ub.es., Bain S; Institute of Life Science, Swansea University, Swansea, UK. S.C.Bain@swansea.ac.uk., Petrie J; Institute of Cardiovascular and Medical Science, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. John.Petrie@glasgow.ac.uk., Franek E; Mossakowski Medical Research Centre, Polish Academy of Sciences and Central Clinical Hospital MSW, Warsaw, Poland. Edward.Franek@cskmswia.pl., Raz I; Diabetes Unit, Internal Medicine Division, Hadassah Hebrew University Hospital, Jerusalem, Israel. ntv502@netvision.net.il., Comlekci A; Department of Internal Medicine, Division of Endocrinology, Inciralti, Izmir, Turkey. comlekci@deu.edu.tr., Jacob S; Praxis für Prävention und Therapie, Kardio Metabolischen Instituts, Villingen-Schwenningen, Germany. prof.dr.jacob@web.de., van Gaal L; Department of Endocrinology, Diabetology, and Metabolism, Faculty of Medicine, Antwerp University Hospital, Edegem, Antwerp, Belgium. Luc.Van.Gaal@uza.be., Baeres FM; Novo Nordisk, Copenhagen, Denmark. FMMB@novonordisk.com., Marso SP; Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Steven.marso@utsouthwestern.edu., Eriksson M; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. Mats.Eriksson@ki.se.

Publikováno v: Cardiovascular diabetology [Cardiovasc Diabetol] 2016 Feb 10; Vol. 15, pp. 29. Date of Electronic Publication: 2016 Feb 10.

LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.

Autor: Steinberg WM; From the *Department of Medicine, George Washington University Medical Center, Rockville, MD; †Department of Internal Medicine/Diabetology, Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany; ‡Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; §Thyroid Unit and Department of Medicine, Massachusetts General Hospital Harvard Medical School, Boston, MA; ║Park Nicollet Institute for Research and Education, International Diabetes Center, Minneapolis, MN; ¶Department of Medicine, Friedrich Alexander University of Erlangen, Erlangen, Germany; #Novo Nordisk, A/S, Bagsvaerd, Denmark; **Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX; and ††Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC., Nauck MA, Zinman B, Daniels GH, Bergenstal RM, Mann JF, Steen Ravn L, Moses AC, Stockner M, Baeres FM, Marso SP, Buse JB

Publikováno v: Pancreas [Pancreas] 2014 Nov; Vol. 43 (8), pp. 1223-31.

Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE).

Autor: Karnieli E; Endocrinology, Diabetes and Metabolism, Rambam Medical Center and Rappaport Faculty of Medicine, Technion, 12 Halia St, Samy Ofer Tower, Fl #8, Haifa, 31096, Israel. eddy@rambam.health.gov.il, Baeres FM, Dzida G, Ji Q, Ligthelm R, Ross S, Svendsen AL, Yale JF

Publikováno v: Drugs & aging [Drugs Aging] 2013 Mar; Vol. 30 (3), pp. 167-75.